

Onxeo announces participation in the Midcap Event On October 2nd and 3rd, 2014 in Paris

Paris (France), Copenhagen (Denmark), September 24, 2014 – Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen - ONXEO), an innovative company specialized in the development of drugs for orphan oncology diseases, announced that it will participate in the Midcap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on Thursday 2nd and Friday 3rd of October, 2014 in Paris (Palais Brongniart, 28, place de la Bourse - 75002 Paris - Entry Vivienne).

During these two days, Onxeo Management team will meet with institutional investors to present the Company and its development strategy.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to "make the difference". The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives. *Key products at advanced development stage are:*

Livatag[®] (Doxorubicin Transdrug[™]): Phase III in hepatocellular carcinoma

Validive[®] (Clonidine Lauriad[®]): Phase II in severe oral mucositis

Beleodaq® (belinostat): Registered and available in the USA for peripheral T-cell lymphoma

For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (http://www.amf-france.org) or on the company's website (www.onxeo.com).

Contacts : Judith Greciet, CEO j.greciet@onxeo.com +33 1 45 58 76 00 Nicolas Fellmann, CFO n.fellmann@onxeo.com +33 1 45 58 76 00 Caroline Carmagnol / Sophie Colin – Alize RP caroline@alizerp.com / scolin@alizerp.com +33 6 64 18 99 59 / +33 6 31 13 76 20